2 Sep

CAFC overturns $1.2 billion damages in another Section 112 blow for biotech genus IP

The Federal Circuit’s invalidation of a key CAR-T therapy patent is just the latest illustration of the dangers posed to broad, functionally-defined genus claims by written description and enablement requirements

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth